{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-142019","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.968402+00:00","generated_at":"2026-06-15T04:16:38.478428+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1","bullets":["Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.","Cash and equivalents $292.1M as of March 31, 2023, expected to fund operations into early 2026.","Dosed first patient in Phase 1 trial of ELVN-002 for HER2-altered NSCLC and other solid tumors.","Enrollment progressing in Phase 1 trial of ELVN-001 for CML; initial safety/efficacy data expected in 2024.","Completed merger with Imara Inc. in February 2023; shares now trade as ELVN on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-142019","json":"https://secwatch.observer/filing/0001193125-23-142019.json","markdown":"https://secwatch.observer/filing/0001193125-23-142019.md","text":"https://secwatch.observer/filing/0001193125-23-142019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/0001193125-23-142019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523142019/d421860d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:16:38.478428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}